Novo Nordisk just filed for FDA fast-track approval on Wegovy 7.2mg—claiming it can deliver 20.7% weight loss vs 2.4% on placebo. The kicker? They're using the CNPV voucher to compress review time from 10-12 months down to just 1-2 months.

Here's what's wild: 33% of users hit 25%+ weight loss on the higher dose. Meanwhile, NVO stock is down 43% YTD while the industry grew 19%—classic pharma move of being too good at your job.

The obesity market is projected to hit $100B by 2030, and the arms race is heating up. Eli Lilly's Zepbound is nipping at Wegovy's heels, and now Pfizer just dropped $10B on Metsera to muscle in. Viking Therapeutics and a bunch of others are also cooking up next-gen candidates.

Catch: CMS just negotiated semaglutide prices down 71% for 2027—that's the real story nobody's talking about. Competition killing margins while demand explodes.